THE DEVELOPMENT OF ERBB2-TARGETED THERAPY FOR ALZHEIMERS DISEASE

doi:10.4066/2249-622X-C3-009

THE DEVELOPMENT OF ERBB2-TARGETED THERAPY FOR ALZHEIMERS DISEASE

Joint Event on International Conference on PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS & 19^th International Conference on CELLULAR AND MOLECULAR MEDICINE & 19^th Annual Congress on PSYCHIATRY AND PSYCHIATRIC DISORDERS
October 19-20 , 2018 | Tokyo , Japan

Yung-Feng Liao, Bo-Jeng Wang, Yun-Wen Chen and Pei-Yi Wu

Institute of Cellular and Organismic Biology, Taiwan

Posters & Accepted Abstracts : Asian J Biomed Pharmaceut Sci

DOI: 10.4066/2249-622X-C3-009

Abstract:

g-Secretase-catalyzed production of amyloid-b (Ab) underlies the pathogenesis of Alzheimer’s disease (AD). To identify genetic modifiers that can selectively affect g-secretase cleavage of APP while sparing notch cleavage, we generated cell-based assays employing bioluminescence resonance energy transfer (BRET) technology to monitor the protein-protein interactions between PS1 and two g-secretase substrates, APP C-terminal fragment (C99), and extracellular domain truncated notch (NΔE). An RNAi screen examining the effects of lentiviral shRNA clones targeting 777 kinases and 237 phosphatases encoded in the human genome identified 14 candidate genes whose downregulation resulted in a selective decrease in the interaction between PS1 and C99. Among those 14 candidate genes, an ErbB2-centered interaction network was found to be the most prominent regulatory signaling network that was predicted to preferentially govern the proteostasis of APP-C99. We further demonstrated that overexpression of ErbB2 upregulates the levels of C99 and AICD effectively. The knockdown of ErbB2 selectively decreased the protein levels of C99, AICD, and secreted Ab40, but not those of NΔE and NICD. Selective suppression of ErbB2 expression by CL-387,785, an ErbB1/2-selective irreversible tyrosine kinase inhibitor, can preferentially attenuate the levels of C99 and AICD, resulting in a significant reduction in Ab production. Down-regulation of ErbB2 by CL-387,785 also resulted in a significant decrease in the levels of C99 and secreted Aβ in both zebrafish and mouse models of AD, through the activation of autophagy. Oral administration of CL-387,785 for 3 wk significantly improves the cognitive functions of APP/presenilin-1 (PS1) transgenic mice. These findings unveil a noncanonical function of ErbB2 in modulating autophagy and establishe ErbB2 as a novel therapeutic target for AD.

Biography:

PDF HTML